ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading Down 2.6% – Time to Sell?

Posted by Paula Ricardo on Mar 6th, 2026

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) fell 2.6% on Thursday . The stock traded as low as $49.20 and last traded at $49.41. 19,727 shares were traded during mid-day trading, a decline of 53% from the average session volume of 41,999 shares. The stock had previously closed at $50.72.

ALPS Medical Breakthroughs ETF Trading Down 2.6%

The business’s fifty day simple moving average is $51.23 and its 200 day simple moving average is $45.65.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Janney Montgomery Scott LLC acquired a new stake in ALPS Medical Breakthroughs ETF in the fourth quarter worth $220,000. Sterling Investment Advisors Ltd. grew its holdings in shares of ALPS Medical Breakthroughs ETF by 81.2% in the 4th quarter. Sterling Investment Advisors Ltd. now owns 14,675 shares of the company’s stock valued at $752,000 after buying an additional 6,575 shares during the period. Connors Investor Services Inc. acquired a new position in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at $338,000. Global Retirement Partners LLC bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at $34,000. Finally, Griffin Asset Management Inc. raised its stake in ALPS Medical Breakthroughs ETF by 1.9% during the 4th quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock worth $1,572,000 after buying an additional 564 shares during the period.

About ALPS Medical Breakthroughs ETF

(Get Free Report)

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.